ReviewFrontiers in cell and developmental biology2026
CRISPR-based next-generation molecular diagnostics for bone infection.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone and joint infections, notably osteomyelitis and periprosthetic joint infections, present a profound clinical challenge characterized by severe morbidity, prolonged hospitalizations, and substantial healthcare costs. Effective management is persistently hindered by diagnostic uncertainty. Conventional microbiological cultures yield false-negative results in up to 50% of cases, largely due to prior antibiotic exposure, biofilm formation, and fastidious organisms. Concurrently, the escalating prevalence of antimicrobial resistance (AMR) among orthopedic pathogens demands rapid and highly accurate diagnostic alternatives. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) technologies have recently emerged as robust nucleic acid detection platforms. These systems offer attomolar sensitivity and single-nucleotide specificity while remaining compatible with portable, instrument-free readout formats. In this review, we critically evaluate the current diagnostic landscape of bone infections, highlighting the limitations of conventional and early molecular methods. We specifically examine how the distinct mechanistic properties of varied Cas effectors (Cas12, Cas13, Cas14, and CasΦ) can transform clinical diagnostics through single-nucleotide polymorphism (SNP) discrimination, RNA-based viability assessment, and PAM-independent detection. Furthermore, we explore the application of these features in stratifying pathogens within culture-negative and polymicrobial infections, directly identifying AMR genes for targeted therapy, and facilitating point-of-care testing in intraoperative environments. Finally, we assess the primary barriers to clinical translation, namely, complex sample preprocessing in bone matrices, the lack of standardized diagnostic thresholds, and the need for prospective studies demonstrating improved patient outcomes, ultimately outlining essential research priorities to transition CRISPR diagnostics from laboratory proof-of-concept to routine orthopedic practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.